Integrated Quantitative Investments LLC Acquires New Shares in Pro-Dex, Inc. (NASDAQ:PDEX)

Integrated Quantitative Investments LLC bought a new position in Pro-Dex, Inc. (NASDAQ:PDEX) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 5,432 shares of the medical instruments supplier’s stock, valued at approximately $254,000. Integrated Quantitative Investments LLC owned approximately 0.17% of Pro-Dex at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of PDEX. Geode Capital Management LLC raised its holdings in shares of Pro-Dex by 9.1% during the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after purchasing an additional 2,296 shares during the last quarter. JPMorgan Chase & Co. grew its position in Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after purchasing an additional 529 shares during the period. O Shaughnessy Asset Management LLC purchased a new stake in Pro-Dex during the 4th quarter valued at $995,000. Ritholtz Wealth Management purchased a new stake in Pro-Dex during the 4th quarter valued at $572,000. Finally, American Century Companies Inc. bought a new position in shares of Pro-Dex during the 4th quarter valued at $558,000. Hedge funds and other institutional investors own 15.28% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com downgraded Pro-Dex from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th.

Insider Buying and Selling at Pro-Dex

In other Pro-Dex news, Director Raymond E. Cabillot sold 1,200 shares of Pro-Dex stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $47.76, for a total transaction of $57,312.00. Following the transaction, the director now owns 359,646 shares of the company’s stock, valued at $17,176,692.96. The trade was a 0.33 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders sold 49,153 shares of company stock valued at $2,270,494. Company insiders own 47.50% of the company’s stock.

Pro-Dex Stock Performance

Shares of NASDAQ PDEX opened at $50.90 on Friday. Pro-Dex, Inc. has a 12-month low of $16.84 and a 12-month high of $59.60. The firm has a market capitalization of $165.98 million, a price-to-earnings ratio of 25.32 and a beta of 0.40. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33. The firm has a 50 day moving average of $41.10 and a 200 day moving average of $40.87.

Pro-Dex (NASDAQ:PDEX) last issued its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. On average, research analysts anticipate that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.